<DOC>
	<DOCNO>NCT00030303</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's white blood cell may make body build immune response kill cancer cell . PURPOSE : Phase I trial study effectiveness vaccine therapy treat patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility vaccination autologous heat shock protein 70 patient chronic phase chronic myelogenous leukemia . - Determine toxicity vaccination patient . OUTLINE : Patients undergo leukapheresis obtain peripheral mononuclear cell ( PMNCs ) . Heat shock protein 70 ( HSP70 ) derive autologous PMNCs . Patients receive HSP70 intradermally weekly 8 week . Patients follow 2 week . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic phase chronic myelogenous leukemia Philadelphia chromosome positive Peripheral blast count great 10 % No molecular remission Less 3 year since initial diagnosis No anticipation requirement bone marrow stem cell transplantation 6 month PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Hemoglobin least 10 g/dL Platelet count least 20,000/mm^3 Hepatic : Bilirubin le 2.0 time upper limit normal ( ULN ) Transaminase le 2.0 time ULN Renal : Creatinine le 2.0 mg/dL Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No significant active infection require hospitalization No serious illness significant behavioral psychological problem would preclude study involvement PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Prior interferon alfa allow No concurrent interferon alfa Chemotherapy : Prior cytarabine cytotoxic agent allow No concurrent cytarabine cytotoxic agent Concurrent hydroxyurea allow Endocrine therapy : No concurrent corticosteroid therapy Radiotherapy : Not specify Surgery : Not specify Other : No concurrent immunosuppressive medication Concurrent imatinib mesylate allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
</DOC>